Article info
PDFEpidemiology and outcomes
Off-label use of rituximab for systemic lupus erythematosus in Europe
- Correspondence to Professor Ronald F van Vollenhoven; ronald.van.vollenhoven{at}ki.se, r.f.vanvollenhoven{at}amc.nl
Citation
Off-label use of rituximab for systemic lupus erythematosus in Europe
Publication history
- Received April 26, 2016
- Revision received June 22, 2016
- Accepted July 31, 2016
- First published September 6, 2016.
Online issue publication
May 01, 2020
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/